CClinicalTrials.gg
CompletedNCT06222424Updated Mar 23, 2026

Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues

An interventional study of outpatient prescription issues in Outpatient Prescription Issues, sponsored by Methodist Health System. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Methodist Health System · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Not applicable
Sex
All
01

Study summary

The study aims to document the utility of Methodist Charlton Medical Center (MCMC's)Emergency Medicine Pharmacist (EMP) Collaborative Practice Agreement (CPA )utilization for the resolution of outpatient prescription issues. Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge.

Read the detailed description

Use of an EMP CPA, which allows for broad prescriptive authority, will assist Emergency Department (ED )workflow by preventing a significant volume of new prescriptions needing to be sent by physician and mid-level providers. Will improve rates of ED re-visits. In addition, this Collaborative Practice Agreement (CPA) will not be associated with a large volume of new prescription errors.

02

Conditions studied

  • Outpatient Prescription Issues
03

In context

Lead sponsor

Methodist Health System is the lead sponsor of 169 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023 and a progress note and documenting the reason for the call and action taken by the EMP.

Exclusion criteria

Exclusion Criteria:

  • CPA actions were misclassified as discharge prescription issue resolutions.
  • Patients with prescriptions pursuant to late culture review, formulation changes not requiring a new prescription, prescription transfers to another pharmacy, or simple retransmission of prescriptions.
  • Patients documented to have left the ED against medical advice.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
350 participants (actual)

Study arms

  • Other
    Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023

    Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge.

    Other: outpatient prescription issues

Interventions

  • Otheroutpatient prescription issues

    Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge

06

What researchers measure

Primary outcomes

  1. Number of prescriptions and medication types sent to outpatient pharmacies

    Number of prescriptions and medication types sent to outpatient pharmacies by EMPs pursuant to outpatient prescription issue resolution.

    Time frame: 2 years

Secondary outcomes

  1. Number of patients returning with complaint or diagnosis related to EMP generated prescriptions

    Proportion of patients returning with a complaint or diagnosis related to index EMP-generated prescriptions at three and six-month time points

    Time frame: 2 years

07

Study locations

1 site
  • Clinical Research Institute at Methodist Health System
    Dallas, Texas 75203, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06222424
Lead sponsor
Methodist Health System
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Dec 15, 2023
Primary completion
Mar 1, 2026
Completion
Mar 15, 2026
Last update
Mar 23, 2026

Study contacts

Kevin Burnham, Pharm.D.
principal investigator · Methodist Health System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion